Baillie Gifford & Co
ENTA icon

Baillie Gifford & Co’s Enanta Pharmaceuticals ENTA Stock Holding History

Baillie Gifford & Co’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-360
Closed -$14.6K – 343
2023
Q1 		$14.6K Buy
360
+42
+13% +$2.01K ﹤0.01% 369
2022
Q4 		$14.8K Hold
318
– – ﹤0.01% 375
2022
Q3 		$16K Hold
318
– – ﹤0.01% 357
2022
Q2 		$15K Hold
318
– – ﹤0.01% 367
2022
Q1 		$23K Buy
+318
New +$20.7K ﹤0.01% 351

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co's ENTA Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Enanta Pharmaceuticals (ENTA) in Q2 2023, closing a stake of 360 shares — an estimated $14.6K sold.

Baillie Gifford & Co first reported a position in ENTA in Q1 2022 and held it in 5 quarters. The position peaked at $23K in Q1 2022. 133 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Enanta Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 360 Enanta Pharmaceuticals shares in Q2 2023, an estimated $14.6K.
  • Baillie Gifford & Co first reported a position in Enanta Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Baillie Gifford & Co's Enanta Pharmaceuticals position peaked at $23K in Q1 2022.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.